Download PDF
Semin Neurol 2017; 37(05): 510-537
DOI: 10.1055/s-0037-1608808
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Neuroimaging in Dementia

Adam M. Staffaroni
1   Department of Neurology, Memory and Aging Center, University of California, San Francisco (UCSF), San Francisco, California
,
Fanny M. Elahi
1   Department of Neurology, Memory and Aging Center, University of California, San Francisco (UCSF), San Francisco, California
,
Dana McDermott
1   Department of Neurology, Memory and Aging Center, University of California, San Francisco (UCSF), San Francisco, California
,
Kacey Marton
1   Department of Neurology, Memory and Aging Center, University of California, San Francisco (UCSF), San Francisco, California
,
Elissaios Karageorgiou
1   Department of Neurology, Memory and Aging Center, University of California, San Francisco (UCSF), San Francisco, California
2   Neurological Institute of Athens, Athens, Greece
,
Simone Sacco
1   Department of Neurology, Memory and Aging Center, University of California, San Francisco (UCSF), San Francisco, California
3   Institute of Radiology, Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
,
Matteo Paoletti
1   Department of Neurology, Memory and Aging Center, University of California, San Francisco (UCSF), San Francisco, California
3   Institute of Radiology, Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
,
Eduardo Caverzasi
1   Department of Neurology, Memory and Aging Center, University of California, San Francisco (UCSF), San Francisco, California
4   Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
,
Christopher P. Hess
5   Division of Neuroradiology, Department of Radiology, University of California, San Francisco (UCSF), California
,
Howard J. Rosen
1   Department of Neurology, Memory and Aging Center, University of California, San Francisco (UCSF), San Francisco, California
,
Michael D. Geschwind
1   Department of Neurology, Memory and Aging Center, University of California, San Francisco (UCSF), San Francisco, California
› Author Affiliations
Further Information

Publication History

Publication Date:
05 December 2017 (online)

   Permissions and Reprints

Abstract

Although the diagnosis of dementia still is primarily based on clinical criteria, neuroimaging is playing an increasingly important role. This is in large part due to advances in techniques that can assist with discriminating between different syndromes. Magnetic resonance imaging remains at the core of differential diagnosis, with specific patterns of cortical and subcortical changes having diagnostic significance. Recent developments in molecular PET imaging techniques have opened the door for not only antemortem but early, even preclinical, diagnosis of underlying pathology. This is vital, as treatment trials are underway for pharmacological agents with specific molecular targets, and numerous failed trials suggest that earlier treatment is needed. This article provides an overview of classic neuroimaging findings as well as new and cutting-edge research techniques that assist with clinical diagnosis of a range of dementia syndromes, with an emphasis on studies using pathologically proven cases.

Keywords

magnetic resonance imaging (MRI) - positron emission tomography (PET) - diffusion tensor imaging (DTI) - neurodegenerative disease
 

  • References

  • 1 Crutch SJ, Schott JM, Rabinovici GD. , et al; Alzheimer's Association ISTAART Atypical Alzheimer's Disease and Associated Syndromes Professional Interest Area. Consensus classification of posterior cortical atrophy. Alzheimers Dement 2017; 13 (08) 870-884 . Doi: 10.1016/j.jalz.2017.01.014
    CrossrefPubMedGoogle Scholar
  • 2 McKhann GM, Knopman DS, Chertkow H. , et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (03) 263-269 . Doi: 10.1016/j.jalz.2011.03.005
    CrossrefPubMedGoogle Scholar
  • 3 Sacks CA, Avorn J, Kesselheim AS. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. N Engl J Med 2017; 376 (18) 1706-1708 . Doi: 10.1056/NEJMp1701047
    CrossrefPubMedGoogle Scholar
  • 4 Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009; 62 (01) 42-52
    CrossrefPubMedGoogle Scholar
  • 5 Ossenkoppele R, Cohn-Sheehy BI, La Joie R. , et al. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. Hum Brain Mapp 2015; 36 (11) 4421-4437 . Doi: 10.1002/hbm.22927 [doi]
    CrossrefPubMedGoogle Scholar
  • 6 Ossenkoppele R, Jansen WJ, Rabinovici GD. , et al; Amyloid PET Study Group. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015; 313 (19) 1939-1949 . Doi: 10.1001/jama.2015.4669 [doi]
    CrossrefPubMedGoogle Scholar
  • 7 Suemoto CK, Ferretti-Rebustini REL, Rodriguez RD. , et al. Neuropathological diagnoses and clinical correlates in older adults in Brazil: a cross-sectional study. Brayne C, ed. PLOS Med 2017; 14 (03) e1002267 . doi:10.1371/journal.pmed.1002267
    CrossrefPubMedGoogle Scholar
  • 8 Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011; 70 (11) 960-969 . Doi: 10.1097/NEN.0b013e318232a379 [doi]
    CrossrefPubMedGoogle Scholar
  • 9 Grinberg LT, Rüb U, Ferretti RE. , et al; Brazilian Brain Bank Study Group. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?. Neuropathol Appl Neurobiol 2009; 35 (04) 406-416 . Doi: 10.1111/j.1365-2990.2009.00997.x [doi]
    CrossrefPubMedGoogle Scholar
  • 10 Frisoni GB, Bocchetta M, Chételat G. , et al; ISTAART's NeuroImaging Professional Interest Area. Imaging markers for Alzheimer disease: which vs how. Neurology 2013; 81 (05) 487-500 . Doi: 10.1212/WNL.0b013e31829d86e8
    CrossrefPubMedGoogle Scholar
  • 11 Hashimoto M, Yasuda M, Tanimukai S. , et al. Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 2001; 57 (08) 1461-1466
    CrossrefPubMedGoogle Scholar
  • 12 van de Pol LA, van der Flier WM, Korf ES, Fox NC, Barkhof F, Scheltens P. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 2007; 69 (15) 1491-1497
    CrossrefPubMedGoogle Scholar
  • 13 Li B, Shi J, Gutman BA. , et al; Alzheimer's Disease Neuroimaging Initiative. Influence of APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-Based ADNI Study. PLoS One 2016; 11 (04) e0152901 . Doi: 10.1371/journal.pone.0152901 [doi]
    CrossrefPubMedGoogle Scholar
  • 14 Choo IH, Lee DY, Oh JS. , et al. Posterior cingulate cortex atrophy and regional cingulum disruption in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2010; 31 (05) 772-779 . Doi: 10.1016/j.neurobiolaging.2008.06.015
    CrossrefPubMedGoogle Scholar
  • 15 Lee SE, Rabinovici GD, Mayo MC. , et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011; 70 (02) 327-340 . Doi: 10.1002/ana.22424
    CrossrefPubMedGoogle Scholar
  • 16 Gorno-Tempini ML, Dronkers NF, Rankin KP. , et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55 (03) 335-346 . Doi: 10.1002/ana.10825
    CrossrefPubMedGoogle Scholar
  • 17 Desikan RS, Rafii MS, Brewer JB, Hess CP. An expanded role for neuroimaging in the evaluation of memory impairment. AJNR Am J Neuroradiol 2013; 34 (11) 2075-2082
    CrossrefPubMedGoogle Scholar
  • 18 Ellis RJ, Olichney JM, Thal LJ. , et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996; 46 (06) 1592-1596 . Doi: 10.1212/WNL.46.6.1592
    CrossrefPubMedGoogle Scholar
  • 19 Yamada M. Cerebral amyloid angiopathy: emerging concepts. J Stroke 2015; 17 (01) 17-30 . Doi: 10.5853/jos.2015.17.1.17 [doi]
    CrossrefPubMedGoogle Scholar
  • 20 Buckner RL, Snyder AZ, Shannon BJ. , et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25 (34) 7709-7717
    CrossrefPubMedGoogle Scholar
  • 21 Karageorgiou E, Lewis SM, McCarten JR. , et al. Canonical correlation analysis of synchronous neural interactions and cognitive deficits in Alzheimer's dementia. J Neural Eng 2012; 9 (05) 056003 . Doi: 10.1088/1741-2560/9/5/056003
    CrossrefPubMedGoogle Scholar
  • 22 Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42 (01) 85-94 . Doi: 10.1002/ana.410420114 [doi]
    CrossrefPubMedGoogle Scholar
  • 23 Jagust W, Thisted R, Devous Sr MDS. , et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 2001; 56 (07) 950-956
    CrossrefPubMedGoogle Scholar
  • 24 Ibáñez V, Pietrini P, Alexander GE. , et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998; 50 (06) 1585-1593 http://www.ncbi.nlm.nih.gov/pubmed/9633698 Accessed June 4, 2017
    CrossrefPubMedGoogle Scholar
  • 25 Sanchez-Catasus CA, Stormezand GN, van Laar PJ, De Deyn PP, Sanchez MA, Dierckx RA. FDG-PET for Prediction of AD Dementia in Mild Cognitive Impairment. A Review of the State of the Art with Particular Emphasis on the Comparison with Other Neuroimaging Modalities (MRI and Perfusion SPECT). Curr Alzheimer Res 2017; 14 (02) 127-142
    CrossrefPubMedGoogle Scholar
  • 26 Lehmann M, Ghosh PM, Madison C. , et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013; 136 (Pt 3): 844-858
    CrossrefPubMedGoogle Scholar
  • 27 Jansen WJ, Ossenkoppele R, Knol DL. , et al; Amyloid Biomarker Study Group. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015; 313 (19) 1924-1938 . Doi: 10.1001/jama.2015.4668
    CrossrefPubMedGoogle Scholar
  • 28 Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS. ; Alzheimer's Disease Neuroimaging Initiative. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA 2017; 317 (22) 2305-2316 . Doi: 10.1001/jama.2017.6669
    CrossrefPubMedGoogle Scholar
  • 29 Ossenkoppele R, Schonhaut DR, Schöll M. , et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 2016; 139 (Pt 5): 1551-1567
    CrossrefPubMedGoogle Scholar
  • 30 Gorelick PB, Scuteri A, Black SE. , et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42 (09) 2672-2713 . Doi: 10.1161/STR.0b013e3182299496
    CrossrefPubMedGoogle Scholar
  • 31 Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci 2013; 5: 17 . Doi: 10.3389/fnagi.2013.00017
    PubMedGoogle Scholar
  • 32 Zaccai J, Ince P, Brayne C. Population-based neuropathological studies of dementia: design, methods and areas of investigation--a systematic review. BMC Neurol 2006; 6: 2 . Doi: 10.1186/1471-2377-6-2
    CrossrefPubMedGoogle Scholar
  • 33 Grinberg LT, Nitrini R, Suemoto CK. , et al. Prevalence of dementia subtypes in a developing country: a clinicopathological study. Clinics (Sao Paulo) 2013; 68 (08) 1140-1145 . Doi: 10.6061/clinics/2013(08)13 [doi]
    CrossrefPubMedGoogle Scholar
  • 34 Korczyn AD. The complex nosological concept of vascular dementia. J Neurol Sci 2002; 203–204: 3-6
    PubMedGoogle Scholar
  • 35 Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277 (10) 813-817
    CrossrefPubMedGoogle Scholar
  • 36 Rosenberg GA, Wallin A, Wardlaw JM. , et al. Consensus statement for diagnosis of subcortical small vessel disease. J Cereb Blood Flow Metab 2016; 36 (01) 6-25 . Doi: 10.1038/jcbfm.2015.172
    CrossrefPubMedGoogle Scholar
  • 37 Jokinen H, Gouw AA, Madureira S. , et al; LADIS Study Group. Incident lacunes influence cognitive decline: the LADIS study. Neurology 2011; 76 (22) 1872-1878 . Doi: 10.1212/WNL.0b013e31821d752f
    CrossrefPubMedGoogle Scholar
  • 38 de Laat KF, Tuladhar AM, van Norden AGW, Norris DG, Zwiers MP, de Leeuw F-E. Loss of white matter integrity is associated with gait disorders in cerebral small vessel disease. Brain 2011; 134 (Pt 1): 73-83 . Doi: 10.1093/brain/awq343
    CrossrefPubMedGoogle Scholar
  • 39 Wardlaw JM, Doubal FN, Valdes-Hernandez M. , et al. Blood-brain barrier permeability and long-term clinical and imaging outcomes in cerebral small vessel disease. Stroke 2013; 44 (02) 525-527 . Doi: 10.1161/STROKEAHA.112.669994
    CrossrefPubMedGoogle Scholar
  • 40 Wardlaw JM. Blood-brain barrier and cerebral small vessel disease. J Neurol Sci 2010; 299 (1-2): 66-71 . Doi: 10.1016/j.jns.2010.08.042
    CrossrefPubMedGoogle Scholar
  • 41 Wardlaw JM, Smith EE, Biessels GJ. , et al; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12 (08) 822-838 . Doi: 10.1016/S1474-4422(13)70124-8
    CrossrefPubMedGoogle Scholar
  • 42 Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neurol 1987; 44 (01) 21-23
    CrossrefPubMedGoogle Scholar
  • 43 Grimmer T, Faust M, Auer F. , et al. White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol Aging 2012; 33 (12) 2766-2773 . Doi: 10.1016/j.neurobiolaging.2012.01.016
    CrossrefPubMedGoogle Scholar
  • 44 Lee S, Viqar F, Zimmerman ME. , et al; Dominantly Inherited Alzheimer Network. White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol 2016; 79 (06) 929-939 . Doi: 10.1002/ana.24647
    CrossrefPubMedGoogle Scholar
  • 45 Lee DY, Fletcher E, Martinez O. , et al. Regional pattern of white matter microstructural changes in normal aging, MCI, and AD. Neurology 2009; 73 (21) 1722-1728 . Doi: 10.1212/WNL.0b013e3181c33afb
    CrossrefPubMedGoogle Scholar
  • 46 Adams HH, Hilal S, Schwingenschuh P. , et al. A priori collaboration in population imaging: The Uniform Neuro-Imaging of Virchow-Robin Spaces Enlargement consortium. Alzheimers Dement (Amst) 2015; 1 (04) 513-520 . Doi: 10.1016/j.dadm.2015.10.004
    PubMedGoogle Scholar
  • 47 Ramirez J, Berezuk C, McNeely AA, Scott CJ, Gao F, Black SE. Visible Virchow-Robin spaces on magnetic resonance imaging of Alzheimer's disease patients and normal elderly from the Sunnybrook Dementia Study. J Alzheimers Dis 2015; 43 (02) 415-424 . Doi: 10.3233/JAD-132528
    PubMedGoogle Scholar
  • 48 Charidimou A, Jaunmuktane Z, Baron JC. , et al. White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy?. Neurology 2014; 82 (01) 57-62 . Doi: 10.1212/01.wnl.0000438225.02729.04 [doi]
    CrossrefPubMedGoogle Scholar
  • 49 Martinez-Ramirez S, Pontes-Neto OM, Dumas AP. , et al. Topography of dilated perivascular spaces in subjects from a memory clinic cohort. Neurology 2013; 80 (17) 1551-1556 . Doi: 10.1212/WNL.0b013e31828f1876
    CrossrefPubMedGoogle Scholar
  • 50 van Veluw SJ, Heringa SM, Kuijf HJ, Koek HL, Luijten PR, Biessels GJ. ; Utrecht Vascular Cognitive Impairment study group. Cerebral cortical microinfarcts at 7Tesla MRI in patients with early Alzheimer's disease. J Alzheimers Dis 2014; 39 (01) 163-167 . Doi: 10.3233/JAD-131040
    CrossrefPubMedGoogle Scholar
  • 51 De Reuck J, Deramecourt V, Auger F. , et al. Post-mortem 7.0-tesla magnetic resonance study of cortical microinfarcts in neurodegenerative diseases and vascular dementia with neuropathological correlates. J Neurol Sci 2014; 346 (1-2): 85-89 . Doi: 10.1016/j.jns.2014.07.061
    CrossrefPubMedGoogle Scholar
  • 52 van Dalen JW, Scuric EE, van Veluw SJ. , et al. Cortical microinfarcts detected in vivo on 3 Tesla MRI: clinical and radiological correlates. Stroke 2015; 46 (01) 255-257 . Doi: 10.1161/STROKEAHA.114.007568
    CrossrefPubMedGoogle Scholar
  • 53 Román GC. Senile dementia of the Binswanger type. A vascular form of dementia in the elderly. JAMA 1987; 258 (13) 1782-1788
    CrossrefPubMedGoogle Scholar
  • 54 Zhang CE, Wong SM, van de Haar HJ. , et al. Blood-brain barrier leakage is more widespread in patients with cerebral small vessel disease. Neurology 2017; 88 (05) 426-432 . Doi: 10.1212/WNL.0000000000003556
    CrossrefPubMedGoogle Scholar
  • 55 Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32 (07) 1139-1151 . Doi: 10.1038/jcbfm.2011.197
    CrossrefPubMedGoogle Scholar
  • 56 Baykara E, Gesierich B, Adam R. , et al; Alzheimer's Disease Neuroimaging Initiative. A Novel Imaging Marker for Small Vessel Disease Based on Skeletonization of White Matter Tracts and Diffusion Histograms. Ann Neurol 2016; 80 (04) 581-592 . Doi: 10.1002/ana.24758
    CrossrefPubMedGoogle Scholar
  • 57 Yan L, Liu CY, Smith RX. , et al. Assessing intracranial vascular compliance using dynamic arterial spin labeling. Neuroimage 2016; 124 (Pt A): 433-441 . Doi: 10.1016/j.neuroimage.2015.09.008
    CrossrefPubMedGoogle Scholar
  • 58 Lu H, Liu P, Yezhuvath U, Cheng Y, Marshall O, Ge Y. MRI mapping of cerebrovascular reactivity via gas inhalation challenges. J Vis Exp 2014; 52306 (94) ••• . Doi: 10.3791/52306
    PubMedGoogle Scholar
  • 59 Schrag M, McAuley G, Pomakian J. , et al. Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol 2010; 119 (03) 291-302 . Doi: 10.1007/s00401-009-0615-z
    CrossrefPubMedGoogle Scholar
  • 60 Seo SW, Hwa Lee B, Kim EJ. , et al. Clinical significance of microbleeds in subcortical vascular dementia. Stroke 2007; 38 (06) 1949-1951 . Doi: 10.1161/STROKEAHA.106.477315
    CrossrefPubMedGoogle Scholar
  • 61 Razvi SSM, Davidson R, Bone I, Muir KW. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry 2005; 76 (05) 739-741 . Doi: 10.1136/jnnp.2004.051847
    CrossrefPubMedGoogle Scholar
  • 62 Narayan SK, Gorman G, Kalaria RN, Ford GA, Chinnery PF. The minimum prevalence of CADASIL in northeast England. Neurology 2012; 78 (13) 1025-1027 . Doi: 10.1212/WNL.0b013e31824d586c
    CrossrefPubMedGoogle Scholar
  • 63 Kalimo H, Ruchoux M-M, Viitanen M, Kalaria RN. CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol 2002; 12 (03) 371-384 http://www.ncbi.nlm.nih.gov/pubmed/12146805 Accessed June 23, 2017
    PubMedGoogle Scholar
  • 64 Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser M-G. Review CADASIL. www.thelancet.com/neurology 2009 ;8. doi:10.1016/S1474-4422(09)70127-9.
    PubMedGoogle Scholar
  • 65 Ghosh M, Balbi M, Hellal F, Dichgans M, Lindauer U, Plesnila N. Pericytes are involved in the pathogenesis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Ann Neurol 2015; 78 (06) 887-900 . Doi: 10.1002/ana.24512
    CrossrefPubMedGoogle Scholar
  • 66 de Vries LS, Mancini GMS. Intracerebral hemorrhage and COL4A1 and COL4A2 mutations, from fetal life into adulthood. Ann Neurol 2012; 71 (04) 439-441 . Doi: 10.1002/ana.23544
    CrossrefPubMedGoogle Scholar
  • 67 Choi JC. Genetics of cerebral small vessel disease. J Stroke 2015; 17 (01) 7-16 . Doi: 10.5853/jos.2015.17.1.7
    CrossrefPubMedGoogle Scholar
  • 68 Meuwissen MEC, Halley DJJ, Smit LS. , et al. The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature. Genet Med 2015; 17 (11) 843-853 . Doi: 10.1038/gim.2014.210
    CrossrefPubMedGoogle Scholar
  • 69 Vahedi K, Alamowitch S. Clinical spectrum of type IV collagen (COL4A1) mutations: a novel genetic multisystem disease. Curr Opin Neurol 2011; 24 (01) 63-68 . Doi: 10.1097/WCO.0b013e32834232c6
    CrossrefPubMedGoogle Scholar
  • 70 Weng Y-C, Sonni A, Labelle-Dumais C. , et al. COL4A1 mutations in patients with sporadic late-onset intracerebral hemorrhage. Ann Neurol 2012; 71 (04) 470-477 . Doi: 10.1002/ana.22682
    CrossrefPubMedGoogle Scholar
  • 71 Rannikmäe K, Davies G, Thomson PA. , et al; METASTROKE Consortium; CHARGE WMH Group; ISGC ICH GWAS Study Collaboration; WMH in Ischemic Stroke GWAS Study Collaboration; International Stroke Genetics Consortium. Common variation in COL4A1/COL4A2 is associated with sporadic cerebral small vessel disease. Neurology 2015; 84 (09) 918-926 . Doi: 10.1212/WNL.0000000000001309
    CrossrefPubMedGoogle Scholar
  • 72 Volonghi I, Pezzini A, Del Zotto E. , et al. Role of COL4A1 in basement-membrane integrity and cerebral small-vessel disease. The COL4A1 stroke syndrome. Curr Med Chem 2010; 17 (13) 1317-1324 http://www.ncbi.nlm.nih.gov/pubmed/20166936 Accessed June 22, 2017
    CrossrefPubMedGoogle Scholar
  • 73 Gould DB, Phalan FC, van Mil SE. , et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 2006; 354 (14) 1489-1496 . Doi: 10.1056/NEJMoa053727
    CrossrefPubMedGoogle Scholar
  • 74 Mann DMA, Snowden JS. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. Brain Pathol 2017; DOI: 10.1111/bpa.12486.
    CrossrefPubMedGoogle Scholar
  • 75 Rascovsky K, Hodges JR, Knopman D. , et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134 (Pt 9): 2456-2477 . Doi: 10.1093/brain/awr179
    CrossrefPubMedGoogle Scholar
  • 76 Hogan DB, Jetté N, Fiest KM. , et al. The Prevalence and Incidence of Frontotemporal Dementia: a Systematic Review. Can J Neurol Sci 2016; 43 (01) (Suppl. 01) S96-S109
    CrossrefPubMedGoogle Scholar
  • 77 Seltman RE, Matthews BR. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs 2012; 26 (10) 841-870 . Doi: 10.2165/11640070-000000000-00000
    CrossrefPubMedGoogle Scholar
  • 78 Knopman DS, Petersen RC, Edland SD, Cha RH, Rocca WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology 2004; 62 (03) 506-508 http://www.ncbi.nlm.nih.gov/pubmed/14872045 Accessed March 22, 2017
    CrossrefPubMedGoogle Scholar
  • 79 Snowden JS, Neary D, Mann DMA. Frontotemporal dementia. Br J Psychiatry 2002; 180: 140-143 http://www.ncbi.nlm.nih.gov/pubmed/11823324 . Accessed March 22, 2017
    CrossrefPubMedGoogle Scholar
  • 80 Lanata SC, Miller BL. The behavioural variant frontotemporal dementia (bvFTD) syndrome in psychiatry. J Neurol Neurosurg Psychiatry 2016; 87 (05) 501-511 . Doi: 10.1136/jnnp-2015-310697.The
    CrossrefPubMedGoogle Scholar
  • 81 Lu PH, Mendez MF, Lee GJ. , et al. Patterns of brain atrophy in clinical variants of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2013; 35 (1-2): 34-50
    CrossrefPubMedGoogle Scholar
  • 82 Suárez J, Tartaglia MC, Vitali P. , et al. Characterizing radiology reports in patients with frontotemporal dementia. Neurology 2009; 73 (13) 1073-1074 . Doi: 10.1212/WNL.0b013e3181b9c8a6
    CrossrefPubMedGoogle Scholar
  • 83 Schroeter ML, Raczka K, Neumann J, Yves von Cramon D. Towards a nosology for frontotemporal lobar degenerations-a meta-analysis involving 267 subjects. Neuroimage 2007; 36 (03) 497-510 . Doi: 10.1016/j.neuroimage.2007.03.024
    CrossrefPubMedGoogle Scholar
  • 84 Pressman PS, Miller BL. Diagnosis and management of behavioral variant frontotemporal dementia. Biol Psychiatry 2014; 75 (07) 574-581 . Doi: 10.1016/j.biopsych.2013.11.006
    CrossrefPubMedGoogle Scholar
  • 85 Cardenas VA, Boxer AL, Chao LL. , et al. Deformation-based morphometry reveals brain atrophy in frontotemporal dementia. Arch Neurol 2007; 64 (06) 873-877 . Doi: 10.1001/archneur.64.6.873
    CrossrefPubMedGoogle Scholar
  • 86 Rohrer JD, Rosen HJ. Neuroimaging in frontotemporal dementia. Int Rev Psychiatry 2013; 25 (02) 221-229 . Doi: 10.3109/09540261.2013.778822
    CrossrefPubMedGoogle Scholar
  • 87 Murray ME, Kouri N, Lin W-L, Jack Jr CR, Dickson DW, Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther 2014; 6 (01) 1 . Doi: 10.1186/alzrt231
    CrossrefPubMedGoogle Scholar
  • 88 Rankin KP, Mayo MC, Seeley WW. , et al. Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease. J Mol Neurosci 2011; 45 (03) 594-608 . Doi: 10.1007/s12031-011-9615-2
    CrossrefPubMedGoogle Scholar
  • 89 Perry DC, Rosen HJ. Frontotemporal dementia. In: Geschwind MD, Racine Belkoura C. , eds. Non-Alzheimer's and Atypical Dementia . West Sussex, UK: John Wiley & Sons, Ltd; 2016: 49-63 . doi:10.1016/j.lpm.2007.04.023
    Google Scholar
  • 90 Lee SE, Seeley WW, Poorzand P. , et al. Clinical characterization of bvFTD due to FUS neuropathology. Neurocase 2012; 18 (04) 305-317 . Doi: 10.1080/13554794.2011.604637
    CrossrefPubMedGoogle Scholar
  • 91 Josephs KA, Whitwell JL, Parisi JE. , et al. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur J Neurol 2010; 17 (07) 969-975 . Doi: 10.1111/j.1468-1331.2010.02975.x
    CrossrefPubMedGoogle Scholar
  • 92 Snowden JS, Hu Q, Rollinson S. , et al. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol 2011; 122 (01) 99-110 . Doi: 10.1007/s00401-011-0816-0
    CrossrefPubMedGoogle Scholar
  • 93 Sha SJ, Takada LT, Rankin KP. , et al. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology 2012; 79 (10) 1002-1011 . Doi: 10.1212/WNL.0b013e318268452e
    CrossrefPubMedGoogle Scholar
  • 94 Snowden JS, Rollinson S, Thompson JC. , et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012; 135 (Pt 3): 693-708 . Doi: 10.1093/brain/awr355
    CrossrefPubMedGoogle Scholar
  • 95 Bocchetta M, Cardoso MJ, Cash DM, Ourselin S, Warren JD, Rohrer JD. Patterns of regional cerebellar atrophy in genetic frontotemporal dementia. Neuroimage Clin 2016; 11: 287-290 . Doi: 10.1016/j.nicl.2016.02.008
    CrossrefPubMedGoogle Scholar
  • 96 van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 2008; 7 (10) 965-974 . Doi: 10.1016/S1474-4422(08)70194-7
    CrossrefPubMedGoogle Scholar
  • 97 Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol 2011; 24 (06) 542-549 . Doi: 10.1097/WCO.0b013e32834cd442
    CrossrefPubMedGoogle Scholar
  • 98 Whitwell JL, Boeve BF, Weigand SD. , et al. Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur J Neurol 2015; 22 (05) 745-752 . Doi: 10.1111/ene.12675
    CrossrefPubMedGoogle Scholar
  • 99 Snowden JS, Adams J, Harris J. , et al. Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16 (7-8): 497-505 . Doi: 10.3109/21678421.2015.1074700
    CrossrefPubMedGoogle Scholar
  • 100 Whitwell JL, Jack Jr CR, Boeve BF. , et al. Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations. Neurology 2009; 73 (13) 1058-1065 . Doi: 10.1212/WNL.0b013e3181b9c8b9
    CrossrefPubMedGoogle Scholar
  • 101 Blair IP, Williams KL, Warraich ST. , et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry 2010; 81 (06) 639-645 . Doi: 10.1136/jnnp.2009.194399
    CrossrefPubMedGoogle Scholar
  • 102 Chao LL, Schuff N, Clevenger EM. , et al. Patterns of white matter atrophy in frontotemporal lobar degeneration. Arch Neurol 2007; 64 (11) 1619-1624 . Doi: 10.1001/archneur.64.11.1619
    CrossrefPubMedGoogle Scholar
  • 103 Daianu M, Mendez MF, Baboyan VG. , et al. An advanced white matter tract analysis in frontotemporal dementia and early-onset Alzheimer's disease. Brain Imaging Behav 2016; 10 (04) 1038-1053 . Doi: 10.1007/s11682-015-9458-5
    CrossrefPubMedGoogle Scholar
  • 104 Mahoney CJA, Simpson IJ, Nicholas JM. , et al. Longitudinal diffusion tensor imaging in frontotemporal dementia. Ann Neurol 2015; 77 (01) 33-46
    CrossrefPubMedGoogle Scholar
  • 105 Möller C, Hafkemeijer A, Pijnenburg YALL. , et al. Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: a two-center study. Neuroimage Clin 2015; 9: 418-429
    CrossrefPubMedGoogle Scholar
  • 106 Tosun D, Schuff N, Rabinovici GD. , et al. Diagnostic utility of ASL-MRI and FDG-PET in the behavioral variant of FTD and AD. Ann Clin Transl Neurol 2016; 3 (10) 740-751 . Doi: 10.1002/acn3.330
    CrossrefPubMedGoogle Scholar
  • 107 Vijverberg EGB, Wattjes MP, Dols A. , et al. Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. J Alzheimers Dis 2016; 53 (04) 1287-1297 . Doi: 10.3233/JAD-160285
    CrossrefPubMedGoogle Scholar
  • 108 Woodward MC, Rowe CC, Jones G, Villemagne VL, Varos TA. Differentiating the frontal presentation of Alzheimer's disease with FDG-PET. J Alzheimers Dis 2015; 44 (01) 233-242 . Doi: 10.3233/JAD-141110
    CrossrefPubMedGoogle Scholar
  • 109 Spina S, Schonhaut DR, Boeve BF. , et al. Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations. Neurology 2017; 88 (08) 758-766 . Doi: 10.1212/WNL.0000000000003636
    CrossrefPubMedGoogle Scholar
  • 110 Smith R, Puschmann A, Schöll M. , et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 2016; 139 (Pt 9): 2372-2379 . Doi: 10.1093/brain/aww163
    CrossrefPubMedGoogle Scholar
  • 111 Bevan Jones WR, Cope TE, Passamonti L. , et al. [(18)F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation. Ann Clin Transl Neurol 2016; 3 (12) 940-947 . Doi: 10.1002/acn3.366
    CrossrefPubMedGoogle Scholar
  • 112 Ng KP, Pascoal TA, Mathotaarachchi S. , et al. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther 2017; 9 (01) 25 . Doi: 10.1186/s13195-017-0253-y
    CrossrefPubMedGoogle Scholar
  • 113 Armstrong MJ, Litvan I, Lang AE. , et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80 (05) 496-503 . Doi: 10.1212/WNL.0b013e31827f0fd1
    CrossrefPubMedGoogle Scholar
  • 114 Kertesz A, Martinez-Lage P, Davidson W, Munoz DG. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000; 55 (09) 1368-1375 http://www.ncbi.nlm.nih.gov/pubmed/11087783 Accessed March 1, 2017
    CrossrefPubMedGoogle Scholar
  • 115 Dutt S, Binney RJ, Heuer HW. , et al; AL-108-231 investigators. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology 2016; 87 (19) 2016-2025 . Doi: 10.1212/WNL.0000000000003305
    CrossrefPubMedGoogle Scholar
  • 116 Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011; 7 (05) 263-272 . Doi: 10.1038/nrneurol.2011.43
    CrossrefPubMedGoogle Scholar
  • 117 Josephs KA, Petersen RC, Knopman DS. , et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66 (01) 41-48 . Doi: 10.1212/01.wnl.0000191307.69661.c3
    CrossrefPubMedGoogle Scholar
  • 118 Whitwell JL, Jack Jr CR, Boeve BF. , et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 2010; 75 (21) 1879-1887 . Doi: 10.1212/WNL.0b013e3181feb2e8
    CrossrefPubMedGoogle Scholar
  • 119 Kobylecki C, Jones M, Thompson JC. , et al. Cognitive-behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia. J Neurol 2015; 262 (04) 916-922 . Doi: 10.1007/s00415-015-7657-z
    CrossrefPubMedGoogle Scholar
  • 120 Shi HC, Zhong JG, Pan PL. , et al. Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies. Neurol Sci 2013; 34 (07) 1049-1055 . Doi: 10.1007/s10072-013-1406-9
    CrossrefPubMedGoogle Scholar
  • 121 Josephs KA, Whitwell JL, Dickson DW. , et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging 2008; 29 (02) 280-289 . Doi: 10.1016/j.neurobiolaging.2006.09.019
    CrossrefPubMedGoogle Scholar
  • 122 Nicoletti G, Caligiuri ME, Cherubini A. , et al. A Fully Automated, Atlas-Based Approach for Superior Cerebellar Peduncle Evaluation in Progressive Supranuclear Palsy Phenotypes. AJNR Am J Neuroradiol 2017; 38 (03) 523-530 . Doi: 10.3174/ajnr.A5048
    CrossrefPubMedGoogle Scholar
  • 123 Tsai RM, Lobach I, Bang J. , et al; AL-108-231 Investigators. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism Relat Disord 2016; 28: 29-35 . Doi: 10.1016/j.parkreldis.2016.04.006
    CrossrefPubMedGoogle Scholar
  • 124 Kim YE, Kang SY, Ma H-I, Ju Y-S, Kim YJ. A Visual Rating Scale for the Hummingbird Sign with Adjustable Diagnostic Validity. J Parkinsons Dis 2015; 5 (03) 605-612 . Doi: 10.3233/JPD-150537
    PubMedGoogle Scholar
  • 125 Worker A, Blain C, Jarosz J. , et al. Diffusion Tensor Imaging of Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy: A Tract-Based Spatial Statistics Study. Kassubek J, ed. PLoS One 2014; 9 (11) e112638 . doi:10.1371/journal.pone.0112638
    CrossrefPubMedGoogle Scholar
  • 126 Agosta F, Galantucci S, Svetel M. , et al. Clinical, cognitive, and behavioural correlates of white matter damage in progressive supranuclear palsy. J Neurol 2014; 261 (05) 913-924
    CrossrefPubMedGoogle Scholar
  • 127 Whitwell JL, Avula R, Master A. , et al. Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. Parkinsonism Relat Disord 2011; 17 (08) 599-605 . Doi: 10.1016/j.parkreldis.2011.05.013
    CrossrefPubMedGoogle Scholar
  • 128 Quattrone A, Nicoletti G, Messina D. , et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008; 246 (01) 214-221 . Doi: 10.1148/radiol.2453061703
    CrossrefPubMedGoogle Scholar
  • 129 Kim BC, Choi S-M, Choi K-H. , et al. MRI measurements of brainstem structures in patients with vascular parkinsonism, progressive supranuclear palsy, and Parkinson's disease. Neurol Sci 2017; 38 (04) 627-633 . Doi: 10.1007/s10072-017-2812-1
    CrossrefPubMedGoogle Scholar
  • 130 Nigro S, Arabia G, Antonini A. , et al. Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. Eur Radiol 2017; 27 (06) 2665-2675 . Doi: 10.1007/s00330-016-4622-x
    CrossrefPubMedGoogle Scholar
  • 131 Tipton PW, Konno T, Broderick DF, Dickson DW, Wszolek ZK. Cerebral peduncle angle: unreliable in differentiating progressive supranuclear palsy from other neurodegenerative diseases. Parkinsonism Relat Disord 2016; 32: 31-35 . Doi: 10.1016/j.parkreldis.2016.08.009
    CrossrefPubMedGoogle Scholar
  • 132 Smith R, Schain M, Nilsson C. , et al. Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord 2017; 32 (01) 108-114 . Doi: 10.1002/mds.26813
    CrossrefPubMedGoogle Scholar
  • 133 Cho H, Choi JY, Hwang MS. , et al. Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord 2017; 32 (01) 134-140 . Doi: 10.1002/mds.26844
    CrossrefPubMedGoogle Scholar
  • 134 Passamonti L, Vázquez Rodríguez P, Hong YT. , et al. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain 2017; 140 (03) 781-791 . Doi: 10.1093/brain/aww340
    PubMedGoogle Scholar
  • 135 Coakeley S, Cho SS, Koshimori Y. , et al. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. J Cereb Blood Flow Metab 2017; 37 (09) 3150-3160
    CrossrefPubMedGoogle Scholar
  • 136 Marquié M, Normandin MD, Meltzer AC. , et al. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol 2017; 81 (01) 117-128 . Doi: 10.1002/ana.24844
    CrossrefPubMedGoogle Scholar
  • 137 Gorno-Tempini ML, Hillis AE, Weintraub S. , et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76 (11) 1006-1014 . Doi: 10.1212/WNL.0b013e31821103e6
    CrossrefPubMedGoogle Scholar
  • 138 Spinelli EG, Mandelli ML. , et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol 2017; 81: 430-443
    CrossrefPubMedGoogle Scholar
  • 139 Santos-Santos MA, Mandelli ML, Binney RJ. , et al. Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. JAMA Neurol 2016; 73 (06) 733-742 . Doi: 10.1001/jamaneurol.2016.0412
    CrossrefPubMedGoogle Scholar
  • 140 Spinelli EG, Mandelli ML, Miller ZA. , et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol 2017; 81 (03) 430-443 . Doi: 10.1002/ana.24885
    CrossrefPubMedGoogle Scholar
  • 141 Harris JM, Gall C, Thompson JC. , et al. Classification and pathology of primary progressive aphasia. Neurology 2013; 81 (21) 1832-1839 . Doi: 10.1212/01.wnl.0000436070.28137.7b
    CrossrefPubMedGoogle Scholar
  • 142 Rabinovici GD, Jagust WJ, Furst AJ. , et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008; 64 (04) 388-401 . Doi: 10.1002/ana.21451
    CrossrefPubMedGoogle Scholar
  • 143 Bisenius S, Mueller K, Diehl-Schmid J. , et al; FTLDc study group. Predicting primary progressive aphasias with support vector machine approaches in structural MRI data. Neuroimage Clin 2017; 14: 334-343
    CrossrefPubMedGoogle Scholar
  • 144 Rohrer JD, Warren JD, Modat M. , et al. Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology 2009; 72 (18) 1562-1569 . Doi: 10.1212/WNL.0b013e3181a4124e
    CrossrefPubMedGoogle Scholar
  • 145 Brambati SM, Rankin KP, Narvid J. , et al. Atrophy progression in semantic dementia with asymmetric temporal involvement: a tensor-based morphometry study. Neurobiol Aging 2009; 30 (01) 103-111 . Doi: 10.1016/j.neurobiolaging.2007.05.014
    CrossrefPubMedGoogle Scholar
  • 146 Brambati SM, Amici S, Racine CA. , et al. Longitudinal gray matter contraction in three variants of primary progressive aphasia: a tenser-based morphometry study. Neuroimage Clin 2015; 8: 345-355 . Doi: 10.1016/j.nicl.2015.01.011
    CrossrefPubMedGoogle Scholar
  • 147 Rogalski E, Cobia D, Harrison TM, Wieneke C, Weintraub S, Mesulam M-M. Progression of language decline and cortical atrophy in subtypes of primary progressive aphasia. Neurology 2011; 76 (21) 1804-1810 . Doi: 10.1212/WNL.0b013e31821ccd3c
    CrossrefPubMedGoogle Scholar
  • 148 Gorno-Tempini ML, Murray RC, Rankin KP, Weiner MW, Miller BL. Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report. Neurocase 2004; 10 (06) 426-436 . Doi: 10.1080/13554790490894011
    CrossrefPubMedGoogle Scholar
  • 149 Greicius MD, Kimmel DL. Neuroimaging insights into network-based neurodegeneration. Curr Opin Neurol 2012; 25 (06) 727-734 . Doi: 10.1097/WCO.0b013e32835a26b3
    CrossrefPubMedGoogle Scholar
  • 150 Whitwell JL, Duffy JR, Strand EA. , et al. Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain Lang 2015; 142: 45-53 . Doi: 10.1016/j.bandl.2015.01.009
    CrossrefPubMedGoogle Scholar
  • 151 Matías-Guiu JA, Cabrera-Martín MN, Moreno-Ramos T. , et al. Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes. J Neurol 2015; 262 (06) 1463-1472 . Doi: 10.1007/s00415-015-7738-z
    CrossrefPubMedGoogle Scholar
  • 152 Mahoney CJ, Downey LE, Ridgway GR. , et al. Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimers Res Ther 2012; 4 (05) 41 . Doi: 10.1186/alzrt144
    CrossrefPubMedGoogle Scholar
  • 153 Agosta F, Scola E, Canu E. , et al. White matter damage in frontotemporal lobar degeneration spectrum. Cereb Cortex 2012; 22 (12) 2705-2714 . Doi: 10.1093/cercor/bhr288
    CrossrefPubMedGoogle Scholar
  • 154 Agosta F, Galantucci S, Magnani G. , et al. MRI signatures of the frontotemporal lobar degeneration continuum. Hum Brain Mapp 2015; 36 (07) 2602-2614 . Doi: 10.1002/hbm.22794
    CrossrefPubMedGoogle Scholar
  • 155 Schwindt GC, Graham NL, Rochon E. , et al. Whole-brain white matter disruption in semantic and nonfluent variants of primary progressive aphasia. Hum Brain Mapp 2013; 34 (04) 973-984 . Doi: 10.1002/hbm.21484
    CrossrefPubMedGoogle Scholar
  • 156 Mandelli ML, Caverzasi E, Binney RJ. , et al. Frontal white matter tracts sustaining speech production in primary progressive aphasia. J Neurosci 2014; 34 (29) 9754-9767 . Doi: 10.1523/JNEUROSCI.3464-13.2014
    CrossrefPubMedGoogle Scholar
  • 157 Charles D, Olm C, Powers J. , et al. Grammatical comprehension deficits in non-fluent/agrammatic primary progressive aphasia. J Neurol Neurosurg Psychiatry 2014; 85 (03) 249-256 . Doi: 10.1136/jnnp-2013-305749
    CrossrefPubMedGoogle Scholar
  • 158 D'Anna L, Mesulam MM, Thiebaut de Schotten M. , et al. Frontotemporal networks and behavioral symptoms in primary progressive aphasia. Neurology 2016; 86 (15) 1393-1399 . Doi: 10.1212/WNL.0000000000002579
    CrossrefPubMedGoogle Scholar
  • 159 Tu S, Leyton CE, Hodges JR, Piguet O, Hornberger M. Divergent Longitudinal Propagation of White Matter Degradation in Logopenic and Semantic Variants of Primary Progressive Aphasia. J Alzheimer's Dis 2015; 49 (03) 853-861 . doi:10.3233/JAD-150626
    PubMedGoogle Scholar
  • 160 Mahoney CJ, Malone IB, Ridgway GR. , et al. White matter tract signatures of the progressive aphasias. Neurobiol Aging 2013; 34 (06) 1687-1699 . Doi: 10.1016/j.neurobiolaging.2012.12.002
    CrossrefPubMedGoogle Scholar
  • 161 Agosta F, Ferraro PM, Canu E. , et al. Differentiation between Subtypes of Primary Progressive Aphasia by Using Cortical Thickness and Diffusion-Tensor MR Imaging Measures. Radiology 2015; 276 (01) 219-227 . Doi: 10.1148/radiol.15141869
    CrossrefPubMedGoogle Scholar
  • 162 McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006; 9 (3, Suppl) 417-423
    CrossrefPubMedGoogle Scholar
  • 163 Aarsland D, Rongve A, Nore SP. , et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord 2008; 26 (05) 445-452 . Doi: 10.1159/000165917
    CrossrefPubMedGoogle Scholar
  • 164 Hogan DB, Fiest KM, Roberts JI. , et al. The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic Review. Can J Neurol Sci 2016; 43 (Suppl. 01) S83-S95 . Doi: 10.1017/cjn.2016.2
    CrossrefPubMedGoogle Scholar
  • 165 Gomperts SN. Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia. Continuum (Minneap Minn) 2016; 22 (2 Dementia): 435-463
    PubMedGoogle Scholar
  • 166 Borroni B, Premi E, Formenti A. , et al. Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia. Parkinsonism Relat Disord 2015; 21 (09) 1049-1055 . Doi: 10.1016/j.parkreldis.2015.06.013
    CrossrefPubMedGoogle Scholar
  • 167 Ballard C, Ziabreva I, Perry R. , et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67 (11) 1931-1934 . Doi: 10.1212/01.wnl.0000249130.63615.cc
    CrossrefPubMedGoogle Scholar
  • 168 Emre M. What causes mental dysfunction in Parkinson's disease?. Mov Disord 2003; 18 (Suppl. 06) S63-S71 . Doi: 10.1002/mds.10565
    CrossrefPubMedGoogle Scholar
  • 169 Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69 (24) 2197-2204 . Doi: 10.1212/01.wnl.0000271090.28148.24
    CrossrefPubMedGoogle Scholar
  • 170 Barker WW, Luis CA, Kashuba A. , et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002; 16 (04) 203-212
    CrossrefPubMedGoogle Scholar
  • 171 Walker L, McAleese KE, Thomas AJ. , et al. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol 2015; 129 (05) 729-748 . Doi: 10.1007/s00401-015-1406-3
    CrossrefPubMedGoogle Scholar
  • 172 Kraybill ML, Larson EB, Tsuang DW. , et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005; 64 (12) 2069-2073 . Doi: 10.1212/01.WNL.0000165987.89198.65
    CrossrefPubMedGoogle Scholar
  • 173 Irwin DJ, Grossman M, Weintraub D. , et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 2017; 16 (01) 55-65 . Doi: 10.1016/S1474-4422(16)30291-5
    CrossrefPubMedGoogle Scholar
  • 174 Nedelska Z, Ferman TJ, Boeve BF. , et al. Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging 2015; 36 (01) 452-461 . Doi: 10.1016/j.neurobiolaging.2014.07.005
    CrossrefPubMedGoogle Scholar
  • 175 Zhong J, Pan P, Dai Z, Shi H. Voxelwise meta-analysis of gray matter abnormalities in dementia with Lewy bodies. Eur J Radiol 2014; 83 (10) 1870-1874 . Doi: 10.1016/j.ejrad.2014.06.014
    CrossrefPubMedGoogle Scholar
  • 176 Watson R, O'Brien JT, Barber R, Blamire AM. Patterns of gray matter atrophy in dementia with Lewy bodies: a voxel-based morphometry study. Int Psychogeriatr 2012; 24 (04) 532-540 . Doi: 10.1017/S1041610211002171
    CrossrefPubMedGoogle Scholar
  • 177 Burton EJ, Karas G, Paling SM. , et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002; 17 (02) 618-630
    CrossrefPubMedGoogle Scholar
  • 178 Whitwell JL, Weigand SD, Shiung MM. , et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007; 130 (Pt 3): 708-719 . Doi: 10.1093/brain/awl388
    CrossrefPubMedGoogle Scholar
  • 179 Brenneis C, Wenning GK, Egger KE. , et al. Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. Neuroreport 2004; 15 (11) 1711-1714
    CrossrefPubMedGoogle Scholar
  • 180 Pan PL, Shi HC, Zhong JG. , et al. Gray matter atrophy in Parkinson's disease with dementia: evidence from meta-analysis of voxel-based morphometry studies. Neurol Sci 2013; 34 (05) 613-619 . Doi: 10.1007/s10072-012-1250-3
    CrossrefPubMedGoogle Scholar
  • 181 Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004; 127 (Pt 4): 791-800 . Doi: 10.1093/brain/awh088
    CrossrefPubMedGoogle Scholar
  • 182 Beyer MK, Larsen JP, Aarsland D. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 2007; 69 (08) 747-754 . Doi: 10.1212/01.wnl.0000269666.62598.1c
    CrossrefPubMedGoogle Scholar
  • 183 Tam CWC, Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005; 64 (05) 861-865 . Doi: 10.1212/01.WNL.0000153070.82309.D4
    CrossrefPubMedGoogle Scholar
  • 184 Kenny ER, Burton EJ, O'Brien JT. A volumetric magnetic resonance imaging study of entorhinal cortex volume in dementia with lewy bodies. A comparison with Alzheimer's disease and Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord 2008; 26 (03) 218-225 . Doi: 10.1159/000153432
    CrossrefPubMedGoogle Scholar
  • 185 Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005; 20 (12) 1571-1576 . Doi: 10.1002/mds.20652
    CrossrefPubMedGoogle Scholar
  • 186 Summerfield C, Junqué C, Tolosa E. , et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005; 62 (02) 281-285 . Doi: 10.1001/archneur.62.2.281
    CrossrefPubMedGoogle Scholar
  • 187 Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology 2013; 80 (09) 857-864 . Doi: 10.1212/WNL.0b013e318284070c
    CrossrefPubMedGoogle Scholar
  • 188 Watson R, Blamire AM, Colloby SJ. , et al. Characterizing dementia with Lewy bodies by means of diffusion tensor imaging. Neurology 2012; 79 (09) 906-914 . Doi: 10.1212/WNL.0b013e318266fc51
    CrossrefPubMedGoogle Scholar
  • 189 Kiuchi K, Morikawa M, Taoka T. , et al. White matter changes in dementia with Lewy bodies and Alzheimer's disease: a tractography-based study. J Psychiatr Res 2011; 45 (08) 1095-1100 . Doi: 10.1016/j.jpsychires.2011.01.011
    CrossrefPubMedGoogle Scholar
  • 190 Nedelska Z, Schwarz CG, Boeve BF. , et al. White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiol Aging 2015; 36 (06) 2010-2017 . Doi: 10.1016/j.neurobiolaging.2015.03.007
    CrossrefPubMedGoogle Scholar
  • 191 Chen B, Fan GG, Liu H, Wang S. Changes in anatomical and functional connectivity of Parkinson's disease patients according to cognitive status. Eur J Radiol 2015; 84 (07) 1318-1324 . Doi: 10.1016/j.ejrad.2015.04.014
    CrossrefPubMedGoogle Scholar
  • 192 Perea RD, Rada RC, Wilson J. , et al. A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease. J Alzheimer's Dis Park 2013; 3: 123 . Doi: 10.4172/2161-0460.1000123
    PubMedGoogle Scholar
  • 193 Kamagata K, Motoi Y, Tomiyama H. , et al. Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis. Eur Radiol 2013; 23 (07) 1946-1955 . Doi: 10.1007/s00330-013-2775-4
    CrossrefPubMedGoogle Scholar
  • 194 Booij J, Tissingh G, Boer GJ. , et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62 (02) 133-140 http://www.ncbi.nlm.nih.gov/pubmed/9048712 Accessed June 22, 2017
    CrossrefPubMedGoogle Scholar
  • 195 Del Sole A, Perini G, Lecchi M, Mariani C, Lucignani G, Clerici F. Correlation between 123I-FP-CIT brain SPECT and parkinsonism in dementia with Lewy bodies: caveat for clinical use. Clin Nucl Med 2015; 40 (01) 32-35 . Doi: 10.1097/RLU.0000000000000602
    CrossrefPubMedGoogle Scholar
  • 196 Walker Z, Jaros E, Walker RWH. , et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007; 78 (11) 1176-1181 . Doi: 10.1136/jnnp.2006.110122
    CrossrefPubMedGoogle Scholar
  • 197 Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB. Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord 2012; 18 (03) 225-229 . Doi: 10.1016/j.parkreldis.2011.09.015
    CrossrefPubMedGoogle Scholar
  • 198 Siepel FJ, Rongve A, Buter TC. , et al. (123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. BMJ Open 2013; 3 (04) e002642 . Doi: 10.1136/bmjopen-2013-002642
    CrossrefPubMedGoogle Scholar
  • 199 van der Zande JJ, Booij J, Scheltens P, Raijmakers PGHM, Lemstra AW. [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 2016; 43 (06) 1060-1066 . Doi: 10.1007/s00259-016-3312-x
    CrossrefPubMedGoogle Scholar
  • 200 O'Brien JT, Colloby S, Fenwick J. , et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61 (06) 919-925 . Doi: 10.1001/archneur.61.6.919
    CrossrefPubMedGoogle Scholar
  • 201 Kantarci K, Lowe VJ, Boeve BF. , et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012; 33 (09) 2091-2105 . Doi: 10.1016/j.neurobiolaging.2011.09.024
    CrossrefPubMedGoogle Scholar
  • 202 Gilman S, Koeppe RA, Little R. , et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol 2005; 191 (Suppl. 01) S95-S103 . Doi: 10.1016/j.expneurol.2004.06.017
    CrossrefPubMedGoogle Scholar
  • 203 Pagano G, Niccolini F, Politis M. Imaging in Parkinson's disease. Clin Med (Lond) 2016; 16 (04) 371-375 . Doi: 10.7861/clinmedicine.16-4-371 (Northfield Il)
    CrossrefPubMedGoogle Scholar
  • 204 Zhang X, Jin H, Padakanti PK. , et al. Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging α-Synuclein. Appl Sci (Basel) 2014; 4 (01) 66-78 . Doi: 10.3390/app4010066
    CrossrefPubMedGoogle Scholar
  • 205 Geschwind MD. Rapidly Progressive Dementia. Continuum (Minneap Minn) 2016; 22 (2 Dementia): 510-537
    PubMedGoogle Scholar
  • 206 Mead S, Rudge P. CJD mimics and chameleons. Pract Neurol 2017; 17 (02) 113-121
    CrossrefPubMedGoogle Scholar
  • 207 Masters CL, Harris JO, Gajdusek DC, Gibbs Jr CJ, Bernoulli C, Asher DM. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979; 5 (02) 177-188 . Doi: 10.1002/ana.410050212
    CrossrefPubMedGoogle Scholar
  • 208 Kovács GG, Puopolo M, Ladogana A. , et al; EUROCJD. Genetic prion disease: the EUROCJD experience. Hum Genet 2005; 118 (02) 166-174 . Doi: 10.1007/s00439-005-0020-1
    CrossrefPubMedGoogle Scholar
  • 209 Ladogana A, Puopolo M, Poleggi A. , et al. High incidence of genetic human transmissible spongiform encephalopathies in Italy. Neurology 2005; 64 (09) 1592-1597 . Doi: 10.1212/01.WNL.0000160118.26865.11
    CrossrefPubMedGoogle Scholar
  • 210 Takada LT, Kim M-O, Cleveland RW. , et al. Genetic prion disease: experience of a rapidly progressive dementia center in the United States and a review of the literature. Am J Med Genet B Neuropsychiatr Genet 2017; 174 (01) 36-69 . Doi: 10.1002/ajmg.b.32505
    CrossrefPubMedGoogle Scholar
  • 211 Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996; 53 (09) 913-920 http://www.ncbi.nlm.nih.gov/pubmed/8815857 Accessed June 22, 2017
    CrossrefPubMedGoogle Scholar
  • 212 Geschwind MD. Prion Diseases. Continuum (Minneap Minn) 2015; 21 (6 Neuroinfectious Disease): 1612-1638
    PubMedGoogle Scholar
  • 213 Wang LH, Bucelli RC, Patrick E. , et al. Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease. J Neurol 2013; 260 (02) 498-506 . Doi: 10.1007/s00415-012-6664-6
    CrossrefPubMedGoogle Scholar
  • 214 Carswell C, Thompson A, Lukic A. , et al. MRI findings are often missed in the diagnosis of Creutzfeldt-Jakob disease. BMC Neurol 2012; 12 (01) 153 . Doi: 10.1186/1471-2377-12-153
    CrossrefPubMedGoogle Scholar
  • 215 Vitali P, MacCagnano E, Caverzasi E, Henry RG, Haman A, Torres-Chae C. , et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology 2011; 76: 1711-1719
    CrossrefPubMedGoogle Scholar
  • 216 Shiga Y, Miyazawa K, Sato S. , et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology 2004; 63 (03) 443-449 http://www.ncbi.nlm.nih.gov/pubmed/15304574 . Accessed June 22, 2017
    CrossrefPubMedGoogle Scholar
  • 217 Young GS, Geschwind MD, Fischbein NJ. , et al. Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 2005; 26 (06) 1551-1562 http://www.ncbi.nlm.nih.gov/pubmed/15956529 . Accessed June 22, 2017
    PubMedGoogle Scholar
  • 218 Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 2012; 11 (07) 618-628 . Doi: 10.1016/S1474-4422(12)70063-7
    CrossrefPubMedGoogle Scholar
  • 219 Bongianni M, Orrù C, Groveman BR. , et al. Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples. JAMA Neurol 2017; 74 (02) 155-162 . Doi: 10.1001/jamaneurol.2016.4614
    CrossrefPubMedGoogle Scholar
  • 220 Jezzard P, Barnett AS, Pierpaoli C. Characterization of and correction for eddy current artifacts in echo planar diffusion imaging. Magn Reson Med 1998; 39 (05) 801-812 http://www.ncbi.nlm.nih.gov/pubmed/9581612 Accessed June 22, 2017
    CrossrefPubMedGoogle Scholar
  • 221 Kong A, Kleinig T, Van der Vliet A. , et al. MRI of sporadic Creutzfeldt-Jakob disease. J Med Imaging Radiat Oncol 2008; 52 (04) 318-324 . Doi: 10.1111/j.1440-1673.2008.01962.x
    CrossrefPubMedGoogle Scholar
  • 222 Cali I, Castellani R, Yuan J. , et al. Classification of sporadic Creutzfeldt-Jakob disease revisited. Brain 2006; 129 (Pt 9): 2266-2277 . Doi: 10.1093/brain/awl224
    CrossrefPubMedGoogle Scholar
  • 223 Meissner B, Kallenberg K, Sanchez-Juan P. , et al. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology 2009; 72 (23) 1994-2001 . Doi: 10.1212/WNL.0b013e3181a96e5d
    CrossrefPubMedGoogle Scholar
  • 224 Caverzasi E, Henry RG, Vitali P. , et al. Application of quantitative DTI metrics in sporadic CJD. Neuroimage Clin 2014; 4: 426-435 . Doi: 10.1016/j.nicl.2014.01.011
    CrossrefPubMedGoogle Scholar
  • 225 Caverzasi E, Mandelli ML, DeArmond SJ. , et al. White matter involvement in sporadic Creutzfeldt-Jakob disease. Brain 2014; 137 (Pt 12): 3339-3354 . Doi: 10.1093/brain/awu298
    CrossrefPubMedGoogle Scholar
  • 226 Paoletti M, Caverzasi E, Mandelli ML. , et al. Sporadic Creutzfeld-Jacob Disease quantitative diffusion profiles and resting state functional correlates. In: ePoster Presented at International Society for Magnetic Resonance in Medicine Annual Meeting; 2017
    PubMedGoogle Scholar
  • 227 Rudge P, Jaunmuktane Z, Adlard P. , et al. Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain 2015; 138 (Pt 11): 3386-3399 . Doi: 10.1093/brain/awv235
    CrossrefPubMedGoogle Scholar
  • 228 Lewis AM, Yu M, DeArmond SJ, Dillon WP, Miller BL, Geschwind MD. Human growth hormone-related iatrogenic Creutzfeldt-Jakob disease with abnormal imaging. Arch Neurol 2006; 63 (02) 288-290 . Doi: 10.1001/archneur.63.2.288
    CrossrefPubMedGoogle Scholar
  • 229 Macfarlane RG, Wroe SJ, Collinge J, Yousry TA, Jäger HR. Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry 2007; 78 (07) 664-670 . Doi: 10.1136/jnnp.2006.094821
    PubMedGoogle Scholar
  • 230 Zeidler M, Sellar RJ, Collie DA. , et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000; 355 (9213): 1412-1418 . Doi: 10.1016/s0140-6736(00)02140-1
    CrossrefPubMedGoogle Scholar
  • 231 Haïk S, Brandel JP, Oppenheim C. , et al. Sporadic CJD clinically mimicking variant CJD with bilateral increased signal in the pulvinar. Neurology 2002; 58 (01) 148-149 http://www.ncbi.nlm.nih.gov/pubmed/11781427 Accessed June 22, 2017
    PubMedGoogle Scholar
  • 232 Martindale J, Geschwind MD, De Armond S. , et al. Sporadic Creutzfeldt-Jakob disease mimicking variant Creutzfeldt-Jakob disease. Arch Neurol 2003; 60 (05) 767-770 . Doi: 10.1001/archneur.60.5.767
    CrossrefPubMedGoogle Scholar
  • 233 Breithaupt M, Romero C, Kallenberg K. , et al. Magnetic resonance imaging in E200K and V210I mutations of the prion protein gene. Alzheimer Dis Assoc Disord 2013; 27 (01) 87-90 . Doi: 10.1097/WAD.0b013e31824d578a
    CrossrefPubMedGoogle Scholar
  • 234 Krasnianski A, Heinemann U, Ponto C. , et al. Clinical findings and diagnosis in genetic prion diseases in Germany. Eur J Epidemiol 2016; 31 (02) 187-196 . Doi: 10.1007/s10654-015-0049-y
    CrossrefPubMedGoogle Scholar
  • 235 Krasnianski A, Bartl M, Sanchez Juan PJ. , et al. Fatal familial insomnia: clinical features and early identification. Ann Neurol 2008; 63 (05) 658-661 . Doi: 10.1002/ana.21358
    CrossrefPubMedGoogle Scholar
  • 236 Shi Q, Zhou W, Chen C. , et al. The features of genetic prion diseases based on Chinese surveillance program. PLoS One 2015; 10 (10) e0139552 . Doi: 10.1371/journal.pone.0139552
    CrossrefPubMedGoogle Scholar
  • 237 Singhal AB, Newstein MC, Budzik R. , et al. Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathy. J Neuroimaging 2003; 13 (01) 79-82 . Doi: 10.1177/1051228402239722
    CrossrefPubMedGoogle Scholar
  • 238 Sener RN. Pantothenate kinase-associated neurodegeneration: MR imaging, proton MR spectroscopy, and diffusion MR imaging findings. Am J Neuroradiol 2003; 24: 1690-1693
    PubMedGoogle Scholar
  • 239 Halavaara J, Brander A, Lyytinen J, Setälä K, Kallela M. Wernicke's encephalopathy: is diffusion-weighted MRI useful?. Neuroradiology 2003; 45 (08) 519-523 . Doi: 10.1007/s00234-003-1043-8
    CrossrefPubMedGoogle Scholar
  • 240 Weiss D, Brockmann K, Nägele T, Gasser T, Krüger R. Rapid emergence of temporal and pulvinar lesions in MELAS mimicking Creutzfeldt-Jakob disease. Neurology 2011; 77 (09) 914 . Doi: 10.1212/WNL.0b013e31822c6275
    CrossrefPubMedGoogle Scholar
  • 241 Geschwind MD, Tan KM, Lennon VA. , et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease. Arch Neurol 2008; 65 (10) 1341-1346 . Doi: 10.1001/archneur.65.10.1341
    PubMedGoogle Scholar
  • 242 Rosenbloom MH, Tartaglia MC, Forner SA. , et al. Metabolic disorders with clinical and radiologic features of sporadic Creutzfeldt-Jakob disease. Neurol Clin Pract 2015; 5 (02) 108-115 . Doi: 10.1212/CPJ.0000000000000114
    CrossrefPubMedGoogle Scholar
  • 243 Chu K, Kang D-W, Kim J-Y, Chang K-H, Lee SK. Diffusion-weighted magnetic resonance imaging in nonconvulsive status epilepticus. Arch Neurol 2001; 58 (06) 993-998 . Doi: 10.1001/archneur.58.6.993
    CrossrefPubMedGoogle Scholar
  • 244 Flanagan EP, Drubach DA, Boeve BF. Autoimmune Dementia and Encephalopathy. In: Pittok SJ, Vincent A. , eds. Handbook of clinical neurology. Netherlands: Elsevier; 2016: 247-267
    Google Scholar
  • 245 Misra UK, Kalita J, Phadke RV. , et al. Usefulness of various MRI sequences in the diagnosis of viral encephalitis. Acta Trop 2010; 116 (03) 206-211 . Doi: 10.1016/j.actatropica.2010.08.007
    CrossrefPubMedGoogle Scholar
  • 246 Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010; 85 (05) 427-432 . Doi: 10.4065/mcp.2009.0590
    CrossrefPubMedGoogle Scholar
  • 247 Geschwind MD, Haman A, Miller BL. Rapidly progressive dementia. Neurol Clin 2007; 25 (03) 783-807 , vii. Doi: 10.1016/j.ncl.2007.04.001
    CrossrefPubMedGoogle Scholar
  • 248 Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J Neurol Sci 1965; 2 (04) 307-327 . Doi: 10.1016/0022-510X(65)90016-X
    CrossrefPubMedGoogle Scholar
  • 249 Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 2005; 57 (3, Suppl) S4-S16 , discussion ii–v
    CrossrefPubMedGoogle Scholar
  • 250 Klinge P, Hellström P, Tans J, Wikkelsø C. ; European iNPH Multicentre Study Group. One-year outcome in the European multicentre study on iNPH. Acta Neurol Scand 2012; 126 (03) 145-153 . Doi: 10.1111/j.1600-0404.2012.01676.x
    CrossrefPubMedGoogle Scholar
  • 251 Craven CL, Toma AK, Mostafa T, Patel N, Watkins LD. The predictive value of DESH for shunt responsiveness in idiopathic normal pressure hydrocephalus. J Clin Neurosci 2016; 34: 294-298 . Doi: 10.1016/j.jocn.2016.09.004
    CrossrefPubMedGoogle Scholar
  • 252 Toma AK, Papadopoulos MC, Stapleton S, Kitchen ND, Watkins LD. Systematic review of the outcome of shunt surgery in idiopathic normal-pressure hydrocephalus. Acta Neurochir (Wien) 2013; 155 (10) 1977-1980 . Doi: 10.1007/s00701-013-1835-5
    CrossrefPubMedGoogle Scholar
  • 253 Toma AK, Watkins LD. Surgical management of idiopathic normal pressure hydrocephalus: a trial of a trial. Br J Neurosurg 2016; 30 (06) 605 . Doi: 10.1080/02688697.2016.1229751
    CrossrefPubMedGoogle Scholar
  • 254 Toma AK, Holl E, Kitchen ND, Watkins LD. Evans' index revisited: the need for an alternative in normal pressure hydrocephalus. Neurosurgery 2011; 68 (04) 939-944 . Doi: 10.1227/NEU.0b013e318208f5e0
    CrossrefPubMedGoogle Scholar
  • 255 Ambarki K, Israelsson H, Wåhlin A, Birgander R, Eklund A, Malm J. Brain ventricular size in healthy elderly: comparison between Evans index and volume measurement. Neurosurgery 2010; 67 (01) 94-99 , discussion 99. Doi: 10.1227/01.NEU.0000370939.30003.D1
    CrossrefPubMedGoogle Scholar
  • 256 García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F. , et al. Brain atrophy in alcoholics: relationship with alcohol intake; liver disease; nutritional status, and inflammation. Alcohol Alcohol 2007; 42 (06) 533-538 . Doi: 10.1093/alcalc/agm065
    CrossrefPubMedGoogle Scholar
  • 257 Brunberg JA, Jacquemont S, Hagerman RJ. , et al. Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. AJNR Am J Neuroradiol 2002; 23 (10) 1757-1766
    PubMedGoogle Scholar
  • 258 Ishii K, Soma T, Shimada K, Oda H, Terashima A, Kawasaki R. Automatic volumetry of the cerebrospinal fluid space in idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Dis Extra 2013; 3 (01) 489-496 . Doi: 10.1159/000357329
    CrossrefPubMedGoogle Scholar
  • 259 Hashimoto M, Ishikawa M, Mori E, Kuwana N. ; Study of INPH on neurological improvement (SINPHONI). Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme: a prospective cohort study. Cerebrospinal Fluid Res 2010; 7 (01) 18 . Doi: 10.1186/1743-8454-7-18
    CrossrefPubMedGoogle Scholar
  • 260 Krauss JK, Regel JP, Vach W, Jüngling FD, Droste DW, Wakhloo AK. Flow void of cerebrospinal fluid in idiopathic normal pressure hydrocephalus of the elderly: can it predict outcome after shunting?. Neurosurgery 1997; 40 (01) 67-73 , discussion 73–74
    PubMedGoogle Scholar
  • 261 Bradley Jr WG. CSF Flow in the Brain in the Context of Normal Pressure Hydrocephalus. AJNR Am J Neuroradiol 2015; 36 (05) 831-838 . Doi: 10.3174/ajnr.A4124
    CrossrefPubMedGoogle Scholar
  • 262 Virhammar J, Laurell K, Cesarini KG, Larsson EM. Preoperative prognostic value of MRI findings in 108 patients with idiopathic normal pressure hydrocephalus. AJNR Am J Neuroradiol 2014; 35 (12) 2311-2318
    CrossrefPubMedGoogle Scholar
  • 263 Del Bigio MR. Neuropathological changes caused by hydrocephalus. Acta Neuropathol 1993; 85 (06) 573-585 . Doi: 10.1007/BF00334666
    CrossrefPubMedGoogle Scholar
  • 264 Tullberg M, Hultin L, Ekholm S, Månsson J-E, Fredman P, Wikkelsø C. White matter changes in normal pressure hydrocephalus and Binswanger disease: specificity, predictive value and correlations to axonal degeneration and demyelination. Acta Neurol Scand 2002; 105 (06) 417-426
    CrossrefPubMedGoogle Scholar
  • 265 Marumoto K, Koyama T, Hosomi M, Kodama N, Miyake H, Domen K. Diffusion tensor imaging in elderly patients with idiopathic normal pressure hydrocephalus or Parkinson's disease: diagnosis of gait abnormalities. Fluids Barriers CNS 2012; 9 (01) 20 . Doi: 10.1186/2045-8118-9-20
    CrossrefPubMedGoogle Scholar
  • 266 Hořínek D, Štěpán-Buksakowska I, Szabó N. , et al. Difference in white matter microstructure in differential diagnosis of normal pressure hydrocephalus and Alzheimer's disease. Clin Neurol Neurosurg 2016; 140: 52-59 . Doi: 10.1016/j.clineuro.2015.11.010
    CrossrefPubMedGoogle Scholar
  • 267 Hoza D, Vlasák A, Hořínek D, Sameš M, Alfieri A. DTI-MRI biomarkers in the search for normal pressure hydrocephalus aetiology: a review. Neurosurg Rev 2015; 38 (02) 239-244 , discussion 244. Doi: 10.1007/s10143-014-0584-0
    CrossrefPubMedGoogle Scholar
  • 268 Siasios I, Kapsalaki EZ, Fountas KN. , et al. The role of diffusion tensor imaging and fractional anisotropy in the evaluation of patients with idiopathic normal pressure hydrocephalus: a literature review. Neurosurg Focus 2016; 41 (03) E12 . Doi: 10.3171/2016.6.FOCUS16192
    PubMedGoogle Scholar
  • 269 Kim MJ, Seo SW, Lee KM. , et al. Differential diagnosis of idiopathic normal pressure hydrocephalus from other dementias using diffusion tensor imaging. AJNR Am J Neuroradiol 2011; 32 (08) 1496-1503 . Doi: 10.3174/ajnr.A2531
    CrossrefPubMedGoogle Scholar
  • 270 Yamada S, Tsuchiya K, Bradley WG. , et al. Current and emerging MR imaging techniques for the diagnosis and management of CSF flow disorders: a review of phase-contrast and time-spatial labeling inversion pulse. AJNR Am J Neuroradiol 2015; 36 (04) 623-630 . Doi: 10.3174/ajnr.A4030
    CrossrefPubMedGoogle Scholar
  • 271 Khoo HM, Kishima H, Tani N. , et al. Default mode network connectivity in patients with idiopathic normal pressure hydrocephalus. J Neurosurg 2016; 124 (02) 350-358 . Doi: 10.3171/2015.1.JNS141633
    CrossrefPubMedGoogle Scholar
  • 272 Gilman S, Wenning GK, Low PA. , et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71 (09) 670-676
    CrossrefPubMedGoogle Scholar
  • 273 Joutsa J, Gardberg M, Röyttä M, Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord 2014; 20 (08) 840-844 . Doi: 10.1016/j.parkreldis.2014.04.019
    CrossrefPubMedGoogle Scholar
  • 274 Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125 (Pt 4): 861-870 http://www.ncbi.nlm.nih.gov/pubmed/11912118 Accessed June 6, 2017
    CrossrefPubMedGoogle Scholar
  • 275 Bürk K, Skalej M, Dichgans J. Pontine MRI hyperintensities (“the cross sign”) are not pathognomonic for multiple system atrophy (MSA). Mov Disord 2001; 16 (03) 535 . Doi: 10.1002/mds.1107
    CrossrefPubMedGoogle Scholar
  • 276 Abe K, Hikita T, Yokoe M, Mihara M, Sakoda S. The “cross” signs in patients with multiple system atrophy: a quantitative study. J Neuroimaging 2006; 16 (01) 73-77 . Doi: 10.1177/1051228405279988
    CrossrefPubMedGoogle Scholar
  • 277 Kasahara S, Miki Y, Kanagaki M. , et al. “Hot cross bun” sign in multiple system atrophy with predominant cerebellar ataxia: a comparison between proton density-weighted imaging and T2-weighted imaging. Eur J Radiol 2012; 81 (10) 2848-2852 . Doi: 10.1016/j.ejrad.2011.12.012
    CrossrefPubMedGoogle Scholar
  • 278 Schrag A, Good CD, Miszkiel K. , et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54 (03) 697-702 . Doi: 10.1212/WNL.55.8.1239-a
    CrossrefPubMedGoogle Scholar
  • 279 Horimoto Y, Aiba I, Yasuda T. , et al. Longitudinal MRI study of multiple system atrophy - when do the findings appear, and what is the course?. J Neurol 2002; 249 (07) 847-854 . Doi: 10.1007/s00415-002-0734-0
    CrossrefPubMedGoogle Scholar
  • 280 Takao M, Kadowaki T, Tomita Y, Yoshida Y, Mihara B. ‘Hot-cross bun sign’ of multiple system atrophy. Intern Med 2007; 46 (22) 1883 . Doi: 10.2169/internalmedicine.46.0514
    CrossrefPubMedGoogle Scholar
  • 281 Mandelli ML, De Simone T, Minati L. , et al. Diffusion tensor imaging of spinocerebellar ataxias types 1 and 2. AJNR Am J Neuroradiol 2007; 28 (10) 1996-2000 . Doi: 10.3174/ajnr.A0716
    CrossrefPubMedGoogle Scholar
  • 282 Loy CT, Sweeney MG, Davis MB. , et al. Spinocerebellar ataxia type 17: extension of phenotype with putaminal rim hyperintensity on magnetic resonance imaging. Mov Disord 2005; 20 (11) 1521-1523 . Doi: 10.1002/mds.20529
    CrossrefPubMedGoogle Scholar
  • 283 Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004; 3 (05) 291-304 . Doi: 10.1016/S1474-4422(04)00737-9
    CrossrefPubMedGoogle Scholar
  • 284 Soares-Fernandes JP, Ribeiro M, Machado A. “Hot cross bun” sign in variant Creutzfeldt-Jakob disease. AJNR Am J Neuroradiol 2009; 30 (03) E37 . Doi: 10.3174/ajnr.A1335
    CrossrefPubMedGoogle Scholar
  • 285 Muqit MM, Mort D, Miskiel KA, Shakir RA. “Hot cross bun” sign in a patient with parkinsonism secondary to presumed vasculitis. J Neurol Neurosurg Psychiatry 2001; 71 (04) 565-566
    CrossrefPubMedGoogle Scholar
  • 286 Tha KK, Terae S, Tsukahara A. , et al. Hyperintense putaminal rim at 1.5 T: prevalence in normal subjects and distinguishing features from multiple system atrophy. BMC Neurol 2012; 12 (01) 39 . Doi: 10.1186/1471-2377-12-39
    CrossrefPubMedGoogle Scholar
  • 287 Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002; 73 (05) 517-523 . Doi: 10.1136/jnnp.73.5.517
    CrossrefPubMedGoogle Scholar
  • 288 Brenneis C, Seppi K, Schocke MF. , et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Disord 2003; 18 (10) 1132-1138 . Doi: 10.1002/mds.10502
    CrossrefPubMedGoogle Scholar
  • 289 Specht K, Minnerop M, Abele M, Reul J, Wüllner U, Klockgether T. In vivo voxel-based morphometry in multiple system atrophy of the cerebellar type. Arch Neurol 2003; 60 (10) 1431-1435 . Doi: 10.1001/archneur.60.10.1431
    CrossrefPubMedGoogle Scholar
  • 290 Brenneis C, Boesch SM, Egger KE. , et al. Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. Mov Disord 2006; 21 (02) 159-165 . Doi: 10.1002/mds.20656
    CrossrefPubMedGoogle Scholar
  • 291 Minnerop M, Specht K, Ruhlmann J. , et al. Voxel-based morphometry and voxel-based relaxometry in multiple system atrophy-a comparison between clinical subtypes and correlations with clinical parameters. Neuroimage 2007; 36 (04) 1086-1095 . Doi: 10.1016/j.neuroimage.2007.04.028
    CrossrefPubMedGoogle Scholar
  • 292 Brenneis C, Egger K, Scherfler C. , et al. Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. J Neurol 2007; 254 (02) 191-196 . Doi: 10.1007/s00415-006-0325-6
    CrossrefPubMedGoogle Scholar
  • 293 Schulz JB, Skalej M, Wedekind D. , et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999; 45 (01) 65-74 http://www.ncbi.nlm.nih.gov/pubmed/9894879 Accessed June 22, 2017
    CrossrefPubMedGoogle Scholar
  • 294 Ngai S, Tang YM, Du L, Stuckey S. Hyperintensity of the middle cerebellar peduncles on fluid-attenuated inversion recovery imaging: variation with age and implications for the diagnosis of multiple system atrophy. AJNR Am J Neuroradiol 2006; 27 (10) 2146-2148
    PubMedGoogle Scholar
  • 295 Lee EA, Cho HI, Kim SS, Lee WY. Comparison of magnetic resonance imaging in subtypes of multiple system atrophy. Parkinsonism Relat Disord 2004; 10 (06) 363-368 . Doi: 10.1016/j.parkreldis.2004.04.008
    CrossrefPubMedGoogle Scholar
  • 296 Bhattacharya K, Saadia D, Eisenkraft B. , et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 2002; 59 (05) 835-842
    PubMedGoogle Scholar
  • 297 Worker A, Blain C, Jarosz J. , et al. Diffusion tensor imaging of Parkinson's disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study. PLoS One 2014; 9 (11) e112638 . Doi: 10.1371/journal.pone.0112638
    CrossrefPubMedGoogle Scholar
  • 298 Schocke MFH, Seppi K, Esterhammer R. , et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002; 58 (04) 575-580 . Doi: 10.1212/WNL.58.4.575
    CrossrefPubMedGoogle Scholar
  • 299 Schocke MFH, Seppi K, Esterhammer R. , et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. Neuroimage 2004; 21 (04) 1443-1451 . Doi: 10.1016/j.neuroimage.2003.12.005
    CrossrefPubMedGoogle Scholar
  • 300 Seppi K, Schocke MFH, Prennschuetz-Schuetzenau K. , et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord 2006; 21 (06) 847-852 . Doi: 10.1002/mds.20843
    CrossrefPubMedGoogle Scholar
  • 301 Nicoletti G, Lodi R, Condino F. , et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006; 129 (Pt 10): 2679-2687 . Doi: 10.1093/brain/awl166
    CrossrefPubMedGoogle Scholar
  • 302 Paviour DC, Thornton JS, Lees AJ, Jäger HR. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord 2007; 22 (01) 68-74 . Doi: 10.1002/mds.21204
    CrossrefPubMedGoogle Scholar
  • 303 Baudrexel S, Seifried C, Penndorf B. , et al. The value of putaminal diffusion imaging versus 18-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy. Mov Disord 2014; 29 (03) 380-387 . Doi: 10.1002/mds.25749
    CrossrefPubMedGoogle Scholar
  • 304 Kanazawa M, Shimohata T, Terajima K. , et al. Quantitative evaluation of brainstem involvement in multiple system atrophy by diffusion-weighted MR imaging. J Neurol 2004; 251 (09) 1121-1124 . Doi: 10.1007/s00415-004-0494-0
    PubMedGoogle Scholar
  • 305 Fulham MJ, Dubinsky RM, Polinsky RJ. , et al. Computed tomography, magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in multiple system atrophy and pure autonomic failure. Clin Auton Res 1991; 1 (01) 27-36 http://www.ncbi.nlm.nih.gov/pubmed/1821662 Accessed June 6, 2017
    CrossrefPubMedGoogle Scholar
  • 306 Bosman T, Van Laere K, Santens P. Anatomically standardised 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging 2003; 30 (01) 16-24 . Doi: 10.1007/s00259-002-1009-9
    CrossrefPubMedGoogle Scholar
  • 307 Cilia R, Marotta G, Benti R, Pezzoli G, Antonini A. Brain SPECT imaging in multiple system atrophy. J Neural Transm (Vienna) 2005; 112 (12) 1635-1645 . Doi: 10.1007/s00702-005-0382-5
    CrossrefPubMedGoogle Scholar
  • 308 Kim YJ, Ichise M, Ballinger JR. , et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002; 17 (02) 303-312 http://www.ncbi.nlm.nih.gov/pubmed/11921116 Accessed June 6, 2017
    CrossrefPubMedGoogle Scholar
  • 309 Perlman S. Evaluation and Management of Ataxic Disorders: An Overview for Physicians . Minneapolis, MN: National Ataxia Foundation; 2007
    Google Scholar
  • 310 Klockgether T, Skalej M, Wedekind D. , et al. Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain 1998; 121 (Pt 9): 1687-1693
    CrossrefPubMedGoogle Scholar
  • 311 Brenneis C, Bösch SM, Schocke M, Wenning GK, Poewe W. Atrophy pattern in SCA2 determined by voxel-based morphometry. Neuroreport 2003; 14 (14) 1799-1802 . Doi: 10.1097/00001756-200310060-00008
    CrossrefPubMedGoogle Scholar
  • 312 Lin IS, Wu RM, Lee-Chen GJ, Shan DE, Gwinn-Hardy K. The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment. Parkinsonism Relat Disord 2007; 13 (04) 246-249 . Doi: 10.1016/j.parkreldis.2006.04.009
    CrossrefPubMedGoogle Scholar
  • 313 Schöls L, Amoiridis G, Epplen JT, Langkafel M, Przuntek H, Riess O. Relations between genotype and phenotype in German patients with the Machado-Joseph disease mutation. J Neurol Neurosurg Psychiatry 1996; 61 (05) 466-470 . Doi: 10.1136/jnnp.61.5.466
    CrossrefPubMedGoogle Scholar
  • 314 Schöls L, Haan J, Riess O, Amoiridis G, Przuntek H. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome?. Neurology 1998; 51 (06) 1603-1607
    CrossrefPubMedGoogle Scholar
  • 315 Lima L, Coutinho P. Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorena Portuguese family. Neurology 1980; 30 (03) 319-322 http://www.ncbi.nlm.nih.gov/pubmed/7189034 Accessed June 6, 2017
    CrossrefPubMedGoogle Scholar
  • 316 Murata Y, Yamaguchi S, Kawakami H. , et al. Characteristic magnetic resonance imaging findings in Machado-Joseph disease. Arch Neurol 1998; 55 (01) 33-37 . Doi: 10.1001/archneur.55.1.33
    CrossrefPubMedGoogle Scholar
  • 317 Harding AE. The clinical features and classification of the late onset autosomal dominant cerebellar ataxias. A study of 11 families, including descendants of the ‘the Drew family of Walworth’. Brain 1982; 105 (Pt 1): 1-28 http://www.ncbi.nlm.nih.gov/pubmed/7066668 Accessed June 6, 2017
    CrossrefPubMedGoogle Scholar
  • 318 Harding AE. “Idiopathic” late onset cerebellar ataxia. A clinical and genetic study of 36 cases. J Neurol Sci 1981; 51 (02) 259-271
    CrossrefPubMedGoogle Scholar
  • 319 Kerber KA, Jen JC, Perlman S, Baloh RW. Late-onset pure cerebellar ataxia: differentiating those with and without identifiable mutations. J Neurol Sci 2005; 238 (1-2): 41-45 . Doi: 10.1016/j.jns.2005.06.006
    CrossrefPubMedGoogle Scholar
  • 320 Wardle M, Majounie E, Muzaimi MB, Williams NM, Morris HR, Robertson NP. The genetic aetiology of late-onset chronic progressive cerebellar ataxia. A population-based study. J Neurol 2009; 256 (03) 343-348 . Doi: 10.1007/s00415-009-0015-2
    CrossrefPubMedGoogle Scholar
  • 321 Brussino A, Gellera C, Saluto A. , et al. FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. Neurology 2005; 64 (01) 145-147 . Doi: 10.1212/01.WNL.0000148723.37489.3F
    CrossrefPubMedGoogle Scholar
  • 322 Bürk K, Bühring U, Schulz JB, Zühlke C, Hellenbroich Y, Dichgans J. Clinical and magnetic resonance imaging characteristics of sporadic cerebellar ataxia. Arch Neurol 2005; 62 (06) 981-985 . Doi: 10.1001/archneur.62.6.981
    PubMedGoogle Scholar
  • 323 Koide R, Onodera O, Ikeuchi T. , et al. Atrophy of the cerebellum and brainstem in dentatorubral pallidoluysian atrophy. Influence of CAG repeat size on MRI findings. Neurology 1997; 49 (06) 1605-1612 . Doi: 10.1212/WNL.49.6.1605
    CrossrefPubMedGoogle Scholar
  • 324 Jacquemont S, Hagerman RJ, Leehey M. , et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003; 72 (04) 869-878 . Doi: 10.1086/374321
    CrossrefPubMedGoogle Scholar
  • 325 Jacquemont S, Farzin F, Hall D. , et al. Aging in individuals with the FMR1 mutation. Am J Ment Retard 2004; 109 (02) 154-164 . Doi: 10.1352/0895-8017(2004)109<154:AIIWTF>2.0.CO;2
    CrossrefPubMedGoogle Scholar
  • 326 Chang CC, Eggers SD, Johnson JK, Haman A, Miller BL, Geschwind MD. Anti-GAD antibody cerebellar ataxia mimicking Creutzfeldt-Jakob disease. Clin Neurol Neurosurg 2007; 109 (01) 54-57 . Doi: 10.1016/j.clineuro.2006.01.009
    CrossrefPubMedGoogle Scholar
  • 327 Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42 (10) 1931-1937 http://www.ncbi.nlm.nih.gov/pubmed/1407575 Accessed June 6, 2017
    CrossrefPubMedGoogle Scholar
  • 328 Aylward EHH, Li Q, Stine OC. , et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997; 48 (02) 394-399 . Doi: 10.1212/WNL.48.2.394
    CrossrefPubMedGoogle Scholar
  • 329 Aylward EH, Nopoulos PC, Ross CA. , et al; PREDICT-HD Investigators and Coordinators of Huntington Study Group. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011; 82 (04) 405-410 . Doi: 10.1136/jnnp.2010.208264
    CrossrefPubMedGoogle Scholar
  • 330 Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry 2008; 79 (02) 130-135 . Doi: 10.1136/jnnp.2007.116244
    CrossrefPubMedGoogle Scholar
  • 331 Apple AC, Possin KL, Satris G. , et al. Quantitative 7T Phase Imaging in Premanifest Huntington Disease. Am J Neuroradiol 2014; 35: 1707-1713
    CrossrefPubMedGoogle Scholar
  • 332 Kim H, Kim JH, Possin KL. , et al. Surface-based morphometry reveals caudate subnuclear structural damage in patients with premotor Huntington disease. Brain Imaging Behav 2017; 11 (05) 1365-1372 . Doi: 10.1007/s11682-016-9616-4
    CrossrefPubMedGoogle Scholar
  • 333 Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson Jr EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44 (06) 559-577 http://www.ncbi.nlm.nih.gov/pubmed/2932539 Accessed June 6, 2017
    CrossrefPubMedGoogle Scholar
  • 334 Rosas HD, Koroshetz WJ, Chen YI. , et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003; 60 (10) 1615-1620 . Doi: 10.1212/WNL.62.3.523-a
    CrossrefPubMedGoogle Scholar
  • 335 Tabrizi SJ, Langbehn DR, Leavitt BR. , et al; TRACK-HD investigators. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009; 8 (09) 791-801 . Doi: 10.1016/S1474-4422(09)70170-X.Biological
    CrossrefPubMedGoogle Scholar
  • 336 Ciarmiello A, Cannella M, Lastoria S. , et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006; 47 (02) 215-222
    PubMedGoogle Scholar
  • 337 Paulsen JS, Magnotta VA, Mikos AE. , et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry 2006; 59 (01) 57-63 . Doi: 10.1016/j.biopsych.2005.06.003
    CrossrefPubMedGoogle Scholar
  • 338 Paulsen JS, Nopoulos PC, Aylward E. , et al; PREDICT-HD Investigators and Coordinators of the Huntington's Study Group (HSG). Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010; 82 (3-4): 201-207 . Doi: 10.1016/j.brainresbull.2010.04.003
    CrossrefPubMedGoogle Scholar
  • 339 Stoffers D, Sheldon S, Kuperman JM, Goldstein J, Corey-Bloom J, Aron AR. Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study. Neurology 2010; 74 (15) 1208-1216 . Doi: 10.1212/WNL.0b013e3181d8c20a
    CrossrefPubMedGoogle Scholar
  • 340 Rosas HD, Tuch DS, Hevelone ND. , et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 2006; 21 (09) 1317-1325 . Doi: 10.1002/mds.20979
    CrossrefPubMedGoogle Scholar
  • 341 Della Nave R, Ginestroni A, Tessa C. , et al. Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study. AJNR Am J Neuroradiol 2010; 31 (09) 1675-1681 . Doi: 10.3174/ajnr.A2128
    CrossrefPubMedGoogle Scholar
  • 342 Bohanna I, Georgiou-Karistianis N, Sritharan A. , et al. Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav 2011; 5 (03) 171-180 . Doi: 10.1007/s11682-011-9121-8
    CrossrefPubMedGoogle Scholar
  • 343 Delmaire C, Dumas EM, Sharman MA. , et al. The structural correlates of functional deficits in early huntington's disease. Hum Brain Mapp 2013; 34 (09) 2141-2153 . Doi: 10.1002/hbm.22055
    CrossrefPubMedGoogle Scholar
  • 344 Paulsen JS, Zimbelman JL, Hinton SC. , et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. AJNR Am J Neuroradiol 2004; 25 (10) 1715-1721
    PubMedGoogle Scholar
  • 345 Reading SAJ, Dziorny AC, Peroutka LA. , et al. Functional brain changes in presymptomatic Huntington's disease. Ann Neurol 2004; 55 (06) 879-883 . Doi: 10.1002/ana.20121
    CrossrefPubMedGoogle Scholar
  • 346 Paulsen JS. Functional imaging in Huntington's disease. Exp Neurol 2009; 216 (02) 272-277
    CrossrefPubMedGoogle Scholar
  • 347 van den Bogaard SJA, Dumas EM, Milles J. , et al. Magnetization transfer imaging in premanifest and manifest Huntington disease. AJNR Am J Neuroradiol 2012; 33 (05) 884-889
    CrossrefPubMedGoogle Scholar
  • 348 Feigin A, Leenders KL, Moeller JR. , et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med 2001; 42 (11) 1591-1595 http://www.ncbi.nlm.nih.gov/pubmed/11696626 Accessed June 22, 2017
    PubMedGoogle Scholar
  • 349 Saft C, Schüttke A, Beste C, Andrich J, Heindel W, Pfleiderer B. fMRI reveals altered auditory processing in manifest and premanifest Huntington's disease. Neuropsychologia 2008; 46 (05) 1279-1289 . Doi: 10.1016/j.neuropsychologia.2007.12.002
    CrossrefPubMedGoogle Scholar
  • 350 Novak MJU, Warren JD, Henley SMD, Draganski B, Frackowiak RS, Tabrizi SJ. Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease. Brain 2012; 135 (Pt 4): 1165-1179 . Doi: 10.1093/brain/aws024
    CrossrefPubMedGoogle Scholar
  • 351 Sturrock A, Laule C, Decolongon J. , et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 2010; 75 (19) 1702-1710 . Doi: 10.1212/WNL.0b013e3181fc27e4
    CrossrefPubMedGoogle Scholar
  • 352 Binney RJ, Pankov A, Marx G. , et al. Data-driven regions of interest for longitudinal change in three variants of frontotemporal lobar degeneration. Brain Behav 2017; 7 (04) e00675 . Doi: 10.1002/brb3.675
    CrossrefPubMedGoogle Scholar
  • 353 Pankov A, Binney RJ, Staffaroni AM. , et al. Data-driven regions of interest for longitudinal change in frontotemporal lobar degeneration. Neuroimage Clin 2015; 12: 332-340 . Doi: 10.1016/j.nicl.2015.08.002
    PubMedGoogle Scholar
  • 354 Dupont A-C, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. Int J Mol Sci 2017; 18 (04) 785 . Doi: 10.3390/ijms18040785
    CrossrefPubMedGoogle Scholar
  • 355 Bullmore ET, Bassett DS. Brain graphs: graphical models of the human brain connectome. Annu Rev Clin Psychol 2011; 7 (01) 113-140 . Doi: 10.1146/annurev-clinpsy-040510-143934
    CrossrefPubMedGoogle Scholar
  • 356 Rosazza C, Minati L. Resting-state brain networks: literature review and clinical applications. Neurol Sci 2011; 32 (05) 773-785 . Doi: 10.1007/s10072-011-0636-y
    CrossrefPubMedGoogle Scholar
  • 357 Jones DT, Knopman DS, Gunter JL. , et al; Alzheimer's Disease Neuroimaging Initiative. Cascading network failure across the Alzheimer's disease spectrum. Brain 2016; 139 (Pt 2): 547-562 . Doi: 10.1093/brain/awv338
    CrossrefPubMedGoogle Scholar
  • 358 Ranasinghe KG, Rankin KP, Pressman PS. , et al. Distinct subtypes of behavioral-variant frontotemporal dementia based on patterns of network degeneration. JAMA Neurol 2016; 73 (09) 1078-1088 . Doi: 10.1001/jamaneurol.2016.2016
    CrossrefPubMedGoogle Scholar
  • 359 Griffa A, Baumann PS, Thiran J-P, Hagmann P. Structural connectomics in brain diseases. Neuroimage 2013; 80: 515-526 . Doi: 10.1016/j.neuroimage.2013.04.056
    CrossrefPubMedGoogle Scholar
  • 360 Sawlani V. Diffusion-weighted imaging and apparent diffusion coefficient evaluation of herpes simplex encephalitis and Japanese encephalitis. J Neurol Sci 2009; 287 (1-2): 221-226 . Doi: 10.1016/j.jns.2009.07.010
    CrossrefPubMedGoogle Scholar
  • 361 Küker W, Nägele T, Schmidt F, Heckl S, Herrlinger U. Diffusion-weighted MRI in herpes simplex encephalitis: a report of three cases. Neuroradiology 2004; 46 (02) 122-125 . Doi: 10.1007/s00234-003-1145-3
    CrossrefPubMedGoogle Scholar
  • 362 Hufnagel A, Weber J, Marks S. , et al. Brain diffusion after single seizures. Epilepsia 2003; 44 (01) 54-63 http://www.ncbi.nlm.nih.gov/pubmed/12581230 Accessed July 20, 2017
    PubMedGoogle Scholar
  • 363 Milligan TA, Zamani A, Bromfield E. Frequency and patterns of MRI abnormalities due to status epilepticus. Seizure 2009; 18 (02) 104-108 . Doi: 10.1016/j.seizure.2008.07.004
    CrossrefPubMedGoogle Scholar
  • 364 Burdette JH, Elster AD, Ricci PE. Acute cerebral infarction: quantification of spin-density and T2 shine-through phenomena on diffusion-weighted MR images. Radiology 1999; 212 (02) 333-339 . Doi: 10.1148/radiology.212.2.r99au36333
    CrossrefPubMedGoogle Scholar